HeraMED Limited
HeraMED Limited, a medical data and technology company, develops, manufactures, and sells home-based maternity monitoring technology in Australia and the United States. It also provides HeraBEAT, a medical device for fetal and maternal heart rate used by pregnant women; and HeraCARE, a remote fetal heart rate monitoring solution. The company has a collaboration agreement with Mayo Clinic for the … Read more
HeraMED Limited (1I4) - Total Assets
Latest total assets as of December 2024: €4.48 Million EUR
Based on the latest financial reports, HeraMED Limited (1I4) holds total assets worth €4.48 Million EUR as of December 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
HeraMED Limited - Total Assets Trend (2018–2024)
This chart illustrates how HeraMED Limited’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
HeraMED Limited - Asset Composition Analysis
Current Asset Composition (December 2024)
HeraMED Limited's total assets of €4.48 Million consist of 82.8% current assets and 17.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 69.8% |
| Accounts Receivable | €34.29K | 0.8% |
| Inventory | €374.83K | 8.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €732.88K | 16.3% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how HeraMED Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: HeraMED Limited's current assets represent 82.8% of total assets in 2024, an increase from 55.1% in 2018.
- Cash Position: Cash and equivalents constituted 69.8% of total assets in 2024, down from 73.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, a decrease from 21.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 16.3% of total assets.
HeraMED Limited Competitors by Total Assets
Key competitors of HeraMED Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
HeraMED Limited - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - HeraMED Limited generates 0.08x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - HeraMED Limited is currently not profitable relative to its asset base.
HeraMED Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.52 | 4.17 | 4.37 |
| Quick Ratio | 3.17 | 4.03 | 4.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €2.66 Million | € 1.78 Million | € 1.82 Million |
HeraMED Limited - Advanced Valuation Insights
This section examines the relationship between HeraMED Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 69.61 |
| Latest Market Cap to Assets Ratio | 3.81 |
| Asset Growth Rate (YoY) | 60.6% |
| Total Assets | €4.48 Million |
| Market Capitalization | $17.10 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values HeraMED Limited's assets at a significant premium ( 3.81x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: HeraMED Limited's assets grew by 60.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for HeraMED Limited (2018–2024)
The table below shows the annual total assets of HeraMED Limited from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €4.48 Million | +60.62% |
| 2023-12-31 | €2.79 Million | -54.31% |
| 2022-12-31 | €6.11 Million | +33.14% |
| 2021-12-31 | €4.59 Million | +10.65% |
| 2020-12-31 | €4.15 Million | -19.38% |
| 2019-12-31 | €5.14 Million | -34.29% |
| 2018-12-31 | €7.83 Million | -- |